ReviewFrontiers in immunology2023
Biomarkers (mRNAs and non-coding RNAs) for the diagnosis and prognosis of rheumatoid arthritis.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Current situation and trend of non-coding RNA in rheumatoid arthritis: a review and bibliometric analysis.Frontiers in immunology · 2023Pooled it
- Review
- Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.Nature reviews. Rheumatology · 2026Review
- Association of Plasma miRNA-7-5p and miRNA-214-5p With Rheumatoid Arthritis Associated Interstitial Lung Disease.International journal of rheumatic diseases · 2026Article
- Cellular miRNA-31 and miRNA-125b as predictors of remission and major disease improvement in patients with early rheumatoid arthritis.Scientific reports · 2026Article
- METTL3-Mediated m6A Regulation of CircINTS4/miR-146b-3p Axis in Rheumatoid Arthritis.Inflammation · 2026Article
- Advances in the Diagnosis of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Integrating Conventional Tools and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
- Exploring the mechanism of action of tripterygium glycosides tablets in the treatment of rheumatoid arthritis based on the Lnc-ENST00000602558/IGF1 signaling pathway.Frontiers in pharmacology · 2026Article
- Epigenetic alterations in rheumatoid arthritis: multilayer mechanisms and translational opportunities.Frontiers in immunology · 2026Review
- Danggui Niantong granules in the treatment of rheumatoid arthritis - a mechanistic approach using ceRNA networks.Frontiers in pharmacology · 2026Article
- Molecular profiling of rheumatoid Arthritis: Expression dynamics of hsa_circ_0092125 andBiochemistry and biophysics reports · 2025Article
- Article
- Research advances of pan-immune inflammation value in rheumatoid arthritis.Frontiers in immunology · 2025Review
- Association of miR-145-5p, miR-143-3p and miR-146a-5p with Simplified Disease Activity Index in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2025Article
- Investigating the regulation of the miR-199a-3p/TGF-β/Smad signaling pathway by BSHXF drug-containing serum combined with ADSCs for delaying intervertebral disc degeneration.Frontiers in pharmacology · 2025Article
- Prognostic role of baseline hemoglobin level for long-term mortality in newly diagnosed rheumatoid arthritis: a cohort study.Frontiers in nutrition · 2025Article
- DENV-1 Infection of Macrophages Induces Pyroptosis and Causes Changes in MicroRNA Expression Profiles.Biomedicines · 2024Article
- Paeoniflorin inhibits the inflammation of rheumatoid arthritis fibroblast-like synoviocytes by downregulating hsa_circ_009012.Heliyon · 2024Article
- LC-MS-based serum metabolomics reveals distinct metabolic signatures in patients with cerebral infarction.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, diagnostic and therapeutic approaches for rheumatoid arthritis (RA) have continued to improve. However, in the advanced stages of the disease, patients are unable to achieve long-term clinical remission and often suffer from systemic multi-organ damage and severe complications. Patients with RA usually have no overt clinical manifestations in the early stages, and by the time a definitive diagnosis is made, the disease is already at an advanced stage. RA is diagnosed clinically and with laboratory tests, including the blood markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) and the autoantibodies rheumatoid factor (RF) and anticitrullinated protein antibodies (ACPA). However, the presence of RF and ACPA autoantibodies is associated with aggravated disease, joint damage, and increased mortality, and these autoantibodies have low specificity and sensitivity. The etiology of RA is unknown, with the pathogenesis involving multiple factors and clinical heterogeneity. The early diagnosis, subtype classification, and prognosis of RA remain challenging, and studies to develop minimally invasive or non-invasive biomarkers in the form of biofluid biopsies are becoming more common. Non-coding RNA (ncRNA) molecules are composed of long non-coding RNAs, small nucleolar RNAs, microRNAs, and circular RNAs, which play an essential role in disease onset and progression and can be used in the early diagnosis and prognosis of RA. In this review of the diagnostic and prognostic approaches to RA disease, we provide an overview of the current knowledge on the subject, focusing on recent advances in mRNA-ncRNA as diagnostic and prognostic biomarkers from the biofluid to the tissue level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.